Media Inquiries

Contact:
Chris Wells
PMC
Phone: 202-580-9780


News

PMC Press Releases

« Back

PMC Board Chair Stephen L. Eck to Pioneer Development of Novel Personalized Oncology Treatment in New Role as CEO of Aravive Biologics


PMC President: Exploration of molecular pathways promises to revolutionize cancer treatment


WASHINGTON (May 10, 2017)

 — 





The Personalized Medicine Coalition (PMC) today congratulates its Board Chair Stephen L. Eck, M.D., Ph.D., on his recent appointment as Aravive Biologics’ new CEO, where Dr. Eck will lead the company’s development of Aravive-S6, a first-in-class therapy designed to treat cancer via a novel molecular pathway known as Gas6/AXL inhibition.

"The exploration of new molecular pathways promises to revolutionize cancer treatment,” said PMC President Edward Abrahams. "Dr. Eck, given his experience leading biomarker development and personalized medicine at several prominent pharmaceutical companies, is well-positioned to spearhead this pioneering work.”

Prior to joining Aravive, Dr. Eck served as vice president, oncology medical sciences at Astellas Pharma Global Development. Dr. Eck had previously led Eli Lilly and Company’s efforts to develop biomarkers and companion diagnostics as vice president, translational medicine and pharmacogenomics. He has also served in a variety of similar oncology and neuroscience drug development leadership roles at Pfizer. 

A board-certified hematologist and fellow at the American Association for the Advancement of Science, Dr. Eck earned a Ph.D. in chemistry from Harvard University and an M.D. from the University of Mississippi School of Medicine.

"I am very excited to be joining Aravive at this point in the company’s development,” Dr. Eck said in a statement released yesterday by Aravive. "Aravive-S6 is a novel and promising agent that has shown in preclinical trials the potential to improve the treatment of cancer in combination with a wide range of other approaches, including chemotherapeutic drugs, radiation, PARP inhibitors and checkpoint inhibitors. I look forward to helping Aravive realize the full potential that I believe Gas6/AXL inhibition can bring to the treatment of cancer.”


Contact:
Christopher J. Wells
cwells@personalizedmedicinecoalition.org
Phone: 202-589-1755

About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.

« Back

Join Today

PMC members shape and advance the future of personalized medicine.
Join Today